COVID-19 Pandemic has become one of the most global health crisis in a century. Governments, NGOs, and public authorities have focused on containing the virus, fast-tracking vaccination programs to keep populations safe, and ensuring that economies recover speedily.
Since the global vaccine campaign commenced in December 2020, DHL has distributed its biggest ever contribution in more than 160 nations, playing a pivotal role in the global vaccination roll-out.
Statementfrom Katja Busch, Chief Commercial Officer DHL
Katja Busch, Chief Commercial Officer DHL stated out that “Looking back at the state of emergency these past nine months, we are honored to be playing our part, seamlessly managing and executing multiple supply chain set-ups without cold chain interruptions or security incidents. We are working across multiple supply chain set-ups and managing direct distributions in certain countries. We implemented new, dedicated, and reliable services at an accelerated speed to ship the highly temperature-sensitive vaccines, as well as ancillary supplies and test kits. In line with our purpose of ‘Connecting people, Improving Lives’, we will continue tapping into our cold chain infrastructure, resilient global network, and deep pharmaceutical logistics knowledge and experience of our people.”
Statement from Thomas Ellmann, Vice President of Life Sciences & Healthcare, DHL Customer Solutions & Innovation
Thomas Ellmann, Vice President of Life Sciences & Healthcare, DHL Customer Solutions & Innovation, stated out that, “Making a meaningful difference is what drives us, and we are proud of our contribution to the enormous task of delivering COVID-19 vaccines and related critical medical supplies to the right place at the right time, worldwide. The current COVID-19 situation clearly demonstrates how collaboration across governments and NGOs, pharmaceutical companies, medical equipment manufacturers, and logistics companies is the only way to beat pandemics, both now and in the future.”
Statement from Claudia Roa, President of Life Sciences & Healthcare atDHL Customer Solutions & Innovation
“Our advantage is that we already had a sophisticated network in place with the necessary healthcare expertise. This allowed us to react swiftly”, explains Claudia Roa, President of Life Sciences & Healthcare at DHL Customer Solutions & Innovation. “We ship the vaccines in special active thermal containers equipped with state-of-the-art GPS temperature trackers to ensure consistent temperatures and provide full transparency throughout the entire journey.”
DHL Global Forwarding in tandem with the DHL Express have been transferring out COVID-19 vaccines via multiple routes across Europe, other global origins to nations across Asia Pacific, South America.
The global immunization drive signifies a crucial instrument in the fight against the virus, and it is critical for containing further virus variants. To attain the high immunization levels, around 10 billion vaccine doses will be essential globally by the end of 2021.
The global distribution of these doses is essential to guarantee that as many individuals as possible have access to vaccines. Besides managing various and complex supply chain set-ups, the sensitive temperature requirements have been a major challenge for logistics experts.
Crucial future centric preparedness
DHL’s white paper “Revisiting Pandemic Resilience” broadcasts that, the logistics infrastructure and capacity built up for the pandemic should be maintained because another 7-9 billion vaccine doses will be needed annually in the coming years to keep (re-)infection rates low and to slow down the pace of virus mutations – not counting seasonal fluctuations.
To be prepared for the future, it is crucial to identify and prevent health crises early through active partnerships, expanded global warning systems, an integrated epidemic prevention plan, and targeted R&D investments.
The firm also aids in expanding and institutionalizing virus containment and countermeasures (e.g., digital contact tracing and national stockpiles) to ensure strategic preparedness and more efficient response times.
To facilitate a speedy roll-out of medication (i.e., diagnostics, therapeutics, and vaccines), governments and industries should maintain “ever-warm” manufacturing capacity, blueprint research, production, and procurement plans, and expand local deployment capabilities.
Press Release received on mail
